阻止CGRP受体:人类血管床之间的差异
Tessa de Vries1, Deirdre M Boucherie1, Antoon van den Bogaerdt2
1Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
扎维杰邦 (Zavegepant) 是一种小分子素基因相关 (CGRP) 受体对手,在人类冠状动脉和中脑膜动脉中表现出类似的效果. 这一发现对于评估新型偏头痛治疗的心血管安全性至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
- 神经科学是一个神经科学.
背景情况:
- 偏头痛治疗越来越多地准素基因相关 (CGRP) 途径.
- 了解CGRP受体对抗剂对心血管组织的影响对于药物安全至关重要.
研究的目的:
- 为了研究zavegepant对CGRP诱导的人类冠状动脉 (HCAs) 放松的影响.
- 为了比较几个CGRP受体对抗剂的效力,包括zavegepant,在HCA和人类中脑膜动脉 (HMMA) 中.
主要方法:
- 隔离的人类冠状动脉被用来评估CGRP诱导的放松在zavegepant的存在.
- 使用甲状腺图谱分析来确定zavegepant的强度 (pA2值) 和作用机制.
- 以往对HCA和HMMA中其他抗剂 (atogepant,olcegepant,rimegepant,telcagepant,obrogepant) 的研究数据与zavegepant的影响进行了比较.
主要成果:
- 在HCA中,Zavegepant的pA2值为9.92±0.24,Schild图形的斜率与单位没有显著差异.
- 扎维杰潘特在HCAs和HMMA中表现出类似的功效.
- 盾牌斜率<1的对手在HMMA中更强大,而斜率接近统一的对手 (如zavegepant) 在两种动脉类型中都表现出一致的强度.
结论:
- 扎维杰潘特作为一种CGRP受体对手,在冠状动脉和脑膜动脉中具有一致的强度.
- 施尔德图形斜率<1表明多个受体在HCAs中CGRP介导的放松中可能参与.
- 建议进一步研究HCA的CGRP受体药理学,以提高未来偏头痛治疗药物的心血管安全性.
更多相关视频
07:14Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
Published on: June 16, 2023
07:28Visualizing the Calcitonin Gene-Related Peptide Immunoreactive Innervation of the Rat Cranial Dura Mater with Immunofluorescence and Neural Tracing
Published on: January 6, 2021
相关概念视频
Local Anesthetics: Differential Sensitivity of Nerve Fibers
Drugs Acting on Autonomic Ganglia: Blockers
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Antihypertensive Drugs: Action of Calcium Channel Blockers
G-Protein Gated Ion Channels
Sensory...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
